Orchestra BioMed Holdings, Inc.

NasdaqGM OBIO

Orchestra BioMed Holdings, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -47.99 M

Orchestra BioMed Holdings, Inc. Operating Cash Flow is USD -47.99 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -9.33% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Orchestra BioMed Holdings, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -43.90 M.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
SV Wall Street
NasdaqGM: OBIO

Orchestra BioMed Holdings, Inc.

CEO Mr. David P. Hochman
IPO Date Aug. 4, 2020
Location United States
Headquarters 150 Union Square Drive
Employees 56
Sector Healthcare
Industries
Biotechnology 3D Printing Clinical Trials Fintech Medical Instruments Pharmaceuticals Robotics Telehealth
Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

StockViz Staff

February 7, 2025

Any question? Send us an email